Adjuvant potency of Astragaloside VII embedded cholesterol nanoparticles for H3N2 influenza vaccine

Basit Öğe Kaydı
dc.contributor.authorGenc, Rukan
dc.contributor.authorYakubogullari, Nilgun
dc.contributor.authorNalbantsoy, Ayse
dc.contributor.authorCoven, Fethiye
dc.contributor.authorBedir, Erdal
dc.date.accessioned2020-12-01T12:05:02Z
dc.date.available2020-12-01T12:05:02Z
dc.date.issued2020
dc.departmentEge Üniversitesien_US
dc.description.abstractAdjuvants are substances that increase the immune response to a given antigen. in the development of novel vaccine adjuvants/systems, saponins are one of the most attractive molecules due to their altered immunomodulatory activities. in this study, we tried to develop PEG (polyethylene glycol)/cholesterol-based lipid nanoparticles (LNPs) to deliver the Astragaloside VII (AST-VII) and potentiate adjuvant properties of AST-VII for the influenza vaccine. in the formation of PEG/cholesterol/AST-VII-based LNPs (PEG300: Chol-AST-VII LNPs), 3 different primary solvents (acetone, ethanol, and chloroform) were evaluated, employing their effects on hydrodynamic particle size, distribution, surface chemistry, and colloidal stability. Prepared nanoparticles were simply admixtured with inactivated influenza antigen (H3N2) and applied to PMA (phorbol 12-myristate 13-acetate)-ionomycin treated human whole blood to evaluate their cytokine release profile. PEG300: Chol-AST-VII LNPs (80.2 +/- 7.7 nm) were obtained using chloroform as a desolvation agent. Co-treatment of PMA-ionomycin with AST-VII and PEG300: Chol-AST-VII LNPs significantly increased the levels of IL-2 and IFN-gamma, compared to PMA-ionomycin alone. in the presence of H3N2, AST-VII was able to augment IL-17A, while PEG300: Chol-AST-VII LNPs stimulated the production of IFN-gamma. Hemolysis was only observed in PEG300: Chol-AST-VII LNPs (250 mu g/mL) treatment. AST-VII and AST-VII-integrated LNPs could be used as efficacious adjuvants for an inactivated H3N2 vaccine in vitro, and cytokine response through Th1/Th17 route was reported.en_US
dc.identifier.doi10.3906/biy-2003-49en_US
dc.identifier.endpage314en_US
dc.identifier.issn1300-0152
dc.identifier.issn1303-6092
dc.identifier.issue5en_US
dc.identifier.scopus2-s2.0-85092531202en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage304en_US
dc.identifier.urihttps://doi.org/10.3906/biy-2003-49
dc.identifier.urihttps://hdl.handle.net/11454/62858
dc.identifier.volume44en_US
dc.identifier.wosWOS:000582626200009en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technical Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal of Biologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectImmunomodulatory activityen_US
dc.subjectnanocarriersen_US
dc.subjectcholesterolen_US
dc.subjecttriterpenoid saponinsen_US
dc.subjectAstragaloside VIIen_US
dc.subjectinfluenzaen_US
dc.titleAdjuvant potency of Astragaloside VII embedded cholesterol nanoparticles for H3N2 influenza vaccineen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu